BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 9531176)

  • 1. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorus control in peritoneal dialysis patients.
    Yavuz A; Ersoy FF; Passadakis PS; Tam P; Evaggelos DM; Katopodis KP; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis GJ; Dombros NA; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis CP; Yavuz M; Tsakiris DJ; Dimitriades AC; Yilmaz ME; Gültekin M; Süleymanlar G; Oreopoulos DG
    Kidney Int Suppl; 2008 Apr; (108):S152-8. PubMed ID: 18379539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild hyperphosphatemia and mortality in hemodialysis patients.
    Rodriguez-Benot A; Martin-Malo A; Alvarez-Lara MA; Rodriguez M; Aljama P
    Am J Kidney Dis; 2005 Jul; 46(1):68-77. PubMed ID: 15983959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.
    Movilli E; Feliciani A; Camerini C; Brunori G; Zubani R; Scolari F; Parrinello G; Cancarini GC
    Nephron Clin Pract; 2005; 101(4):c161-7. PubMed ID: 16103720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.
    Block GA
    Clin Nephrol; 2000 Oct; 54(4):318-24. PubMed ID: 11076108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.